Kbc Group Nv Kura Oncology, Inc. Transaction History

Kbc Group Nv

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$12.22 - $19.57 $31,161 - $49,903	-2,550 Closed	0 $0
Q3 2020 Oct 28, 2020	SELL	$16.3 - $30.64 $37,490 - $70,472	-2,300 Reduced 47.42%	2,550 $78,000
Q4 2019 Feb 11, 2020	BUY	$12.97 - $15.94 $32,100 - $39,451	2,475 Added 104.21%	4,850 $67,000
Q3 2019 Nov 07, 2019	BUY	$14.75 - $20.87 $7,743 - $10,956	525 Added 28.38%	2,375 $36,000
Q2 2019 Dec 03, 2019	BUY	$14.71 - $19.79 $27,213 - $36,611	1,850 New	1,850 $36,000
Q2 2019 Jul 30, 2019	SELL	$14.71 - $19.79 $27,213 - $36,611	-1,850 Closed	0 $0
Q1 2019 Dec 03, 2019	BUY	$13.73 - $16.87 $25,400 - $31,209	1,850 New	1,850 $31,000

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $603M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.